Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$7.73 - $10.57 $386,500 - $528,500
50,000 New
50,000 $450,000
Q4 2022

Feb 14, 2023

BUY
$4.2 - $14.24 $420,000 - $1.42 Million
100,000 New
100,000 $676,000

Others Institutions Holding KALV

About KalVista Pharmaceuticals, Inc.


  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $220M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.